MX371384B - Receptor antigenico quimerico. - Google Patents
Receptor antigenico quimerico.Info
- Publication number
- MX371384B MX371384B MX2017010552A MX2017010552A MX371384B MX 371384 B MX371384 B MX 371384B MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 371384 B MX371384 B MX 371384B
- Authority
- MX
- Mexico
- Prior art keywords
- antigen receptor
- chimeric antigen
- car
- association
- domain
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 125000006850 spacer group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
| PCT/GB2016/050795 WO2016151315A1 (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010552A MX2017010552A (es) | 2018-03-14 |
| MX371384B true MX371384B (es) | 2020-01-28 |
Family
ID=53052211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010552A MX371384B (es) | 2015-03-23 | 2016-03-22 | Receptor antigenico quimerico. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11058722B2 (enExample) |
| EP (1) | EP3274366B8 (enExample) |
| JP (3) | JP6675417B2 (enExample) |
| KR (1) | KR102174280B1 (enExample) |
| CN (1) | CN107406518B (enExample) |
| AU (1) | AU2016238583B2 (enExample) |
| BR (1) | BR112017018252A2 (enExample) |
| CA (1) | CA2978852C (enExample) |
| CL (1) | CL2017002413A1 (enExample) |
| DK (1) | DK3274366T3 (enExample) |
| ES (1) | ES2773527T3 (enExample) |
| GB (1) | GB201504840D0 (enExample) |
| HU (1) | HUE047929T2 (enExample) |
| IL (1) | IL254254B (enExample) |
| MX (1) | MX371384B (enExample) |
| PL (1) | PL3274366T3 (enExample) |
| PT (1) | PT3274366T (enExample) |
| RU (1) | RU2752880C2 (enExample) |
| SG (1) | SG11201706940QA (enExample) |
| WO (1) | WO2016151315A1 (enExample) |
| ZA (1) | ZA201705682B (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| CN114634943A (zh) | 2015-05-18 | 2022-06-17 | T细胞受体治疗公司 | 使用融合蛋白对tcr重编程的组合物和方法 |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
| EP3494138A1 (en) | 2016-08-02 | 2019-06-12 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB2564823B8 (en) | 2016-10-07 | 2022-06-29 | Tcr2 Therapeutics Inc | Compositions and methods for TCR reprogramming using fusion proteins |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| KR102624509B1 (ko) | 2017-03-27 | 2024-01-12 | 싱가포르국립대학교 | 자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주 |
| EP3600356A4 (en) | 2017-03-27 | 2020-12-23 | National University of Singapore | TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY |
| CA3056942A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
| US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
| CN110914289B (zh) | 2017-05-12 | 2024-05-14 | 克里斯珀医疗股份公司 | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 |
| AU2018311345A1 (en) * | 2017-08-02 | 2020-02-27 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed |
| WO2019086394A1 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | The compbody - a multivalent target binder |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| PE20210666A1 (es) | 2018-05-11 | 2021-03-31 | Crispr Therapeutics Ag | Metodos y composiciones para tratar el cancer |
| EP3794034A1 (en) | 2018-05-15 | 2021-03-24 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| EP3836944A4 (en) * | 2018-08-16 | 2022-05-11 | Memorial Sloan Kettering Cancer Center | LEUCINE ZIPPER BASED COMPOSITIONS AND METHODS OF USE |
| CN112601758A (zh) | 2018-08-29 | 2021-04-02 | 新加坡国立大学 | 特异性刺激经基因修饰免疫细胞的存活和扩增的方法 |
| CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
| CA3113896A1 (en) | 2018-09-27 | 2020-04-02 | Autolus Limited | Chimeric antigen receptor |
| EP3860643A1 (en) * | 2018-10-05 | 2021-08-11 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
| CA3112310C (en) * | 2018-10-05 | 2025-05-06 | Universitat Fur Bodenkultur Wien | CHIMERIC ANTIGEN RECEPTOR GROUP (CAR) |
| GB201817822D0 (en) | 2018-10-31 | 2018-12-19 | Autolus Ltd | Binding domain |
| CN113891718B (zh) * | 2019-02-21 | 2025-01-28 | 杭州天康麦生物技术有限公司 | 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| CN121102493A (zh) | 2019-03-21 | 2025-12-12 | 瑞泽恩制药公司 | 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合 |
| EA202192975A1 (ru) | 2019-04-30 | 2022-02-01 | Криспр Терапьютикс Аг | Аллогенная клеточная терапия b-клеточных злокачественных новообразований с применением генетически сконструированных т-клеток, нацеливающихся на cd19 |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| US20250288672A1 (en) * | 2021-03-24 | 2025-09-18 | Raymond Liu | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
| GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
| WO2025160340A2 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
| WO2010102518A1 (zh) * | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | 一种融合蛋白多聚体 |
| KR101156085B1 (ko) * | 2010-01-29 | 2012-06-20 | 국립암센터 | ４－１ｂｂ리간드（４－１ｂｂｌ）오중합체 및 이의 용도 |
| US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
| KR101956751B1 (ko) * | 2011-10-07 | 2019-03-11 | 고쿠리츠다이가쿠호진 미에다이가쿠 | 키메라 항원 수용체 |
| EP2855666B1 (en) * | 2012-05-25 | 2019-12-04 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| AU2013312838B2 (en) * | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| PL3300745T3 (pl) * | 2013-02-15 | 2020-03-31 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
| CA2933707A1 (en) * | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| EP3626748A1 (en) | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en not_active Ceased
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en not_active Ceased
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active Active
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja not_active Expired - Fee Related
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX371384B (es) | Receptor antigenico quimerico. | |
| EP3743513A4 (en) | NK-92 CELLS MODIFIED BY A CHEMICAL ANTIGENIC RECEPTOR | |
| MX377283B (es) | Célula t o nk que coexpresa un receptor antigénico quimérico (car). | |
| MX2017009182A (es) | Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas. | |
| MX387135B (es) | Células t de receptor de antígeno quimérico co-estimulador que toman como diana a il13r-alfa-2. | |
| MX2022002959A (es) | Anticuerpos anti-tigit y metodos de uso. | |
| PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
| MX376026B (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
| MX390385B (es) | Anticuerpos anti-pd-l1. | |
| MX389021B (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
| UY32501A (es) | Anticuerpo antagonista específico para el heterodímero alfa4-beta7 | |
| DK3389699T3 (da) | Kimæriske og humaniserede anti-humane CTLA4-monoklonale antistoffer og anvendelser deraf | |
| EP3746547A4 (en) | ELIMINATION OF POSITIVE MALIGNITIES FOR PD-L1 BY NK CELLS EXPRESSING A PD-L1 CHEMERIC ANTIGEN RECEPTOR | |
| CL2017003195A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso. | |
| IL265219A (en) | Chimeric antigen receptors comprising bcma-specific fibronectin type iii domains and uses thereof | |
| MX373779B (es) | Receptor quimérico de antígeno anti-cd19 humanizado. | |
| PH12015502572A1 (en) | Chimeric fvii-xten molecules and uses thereof | |
| MX384198B (es) | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. | |
| DK3016681T3 (da) | Humaniserede eller kimære CD3-antistoffer | |
| CL2016002195A1 (es) | Receptor antigénico quimérico car con dominios de unión a antígenos a la región constante del receptor de células t beta | |
| EP4368704A3 (en) | Cell | |
| MX393455B (es) | Anticuerpos anti-cd40 y sus usos. | |
| MX387324B (es) | Variantes de regiones fc de igg1 de humano y usos de las mismas. | |
| CL2014000449A1 (es) | Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos. | |
| UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: AUTOLUS LTD Owner name: RESPIVERT LTD. |
|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: AUTOLUS LIMITED |